Guidelines for therapy of autoimmune liver disease

Hiromi Ishibashi, Atsumasa Komori, Shinji Shimoda, M. Eric Gershwin

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

Original languageEnglish (US)
Pages (from-to)214-226
Number of pages13
JournalSeminars in Liver Disease
Volume27
Issue number2
DOIs
StatePublished - May 2007
Externally publishedYes

Fingerprint

Autoimmune Diseases
Liver Diseases
Guidelines
Therapeutics
Ursodeoxycholic Acid
Autoimmune Hepatitis
Sclerosing Cholangitis
Immunomodulation
Biliary Liver Cirrhosis
Cholestasis
Azathioprine
Liver Transplantation
Adrenal Cortex Hormones
Fibrosis

Keywords

  • Autoimmune hepatitis
  • Guideline
  • Overlapping syndrome
  • Primary biliary cirrhosis
  • Primary sclerosing cholangitis
  • Treatment

ASJC Scopus subject areas

  • Hepatology

Cite this

Guidelines for therapy of autoimmune liver disease. / Ishibashi, Hiromi; Komori, Atsumasa; Shimoda, Shinji; Gershwin, M. Eric.

In: Seminars in Liver Disease, Vol. 27, No. 2, 05.2007, p. 214-226.

Research output: Contribution to journalArticle

Ishibashi, Hiromi ; Komori, Atsumasa ; Shimoda, Shinji ; Gershwin, M. Eric. / Guidelines for therapy of autoimmune liver disease. In: Seminars in Liver Disease. 2007 ; Vol. 27, No. 2. pp. 214-226.
@article{59a975da0ea14b75b1b344fd87b1da51,
title = "Guidelines for therapy of autoimmune liver disease",
abstract = "The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.",
keywords = "Autoimmune hepatitis, Guideline, Overlapping syndrome, Primary biliary cirrhosis, Primary sclerosing cholangitis, Treatment",
author = "Hiromi Ishibashi and Atsumasa Komori and Shinji Shimoda and Gershwin, {M. Eric}",
year = "2007",
month = "5",
doi = "10.1055/s-2007-979472",
language = "English (US)",
volume = "27",
pages = "214--226",
journal = "Seminars in Liver Disease",
issn = "0272-8087",
publisher = "Thieme Medical Publishers",
number = "2",

}

TY - JOUR

T1 - Guidelines for therapy of autoimmune liver disease

AU - Ishibashi, Hiromi

AU - Komori, Atsumasa

AU - Shimoda, Shinji

AU - Gershwin, M. Eric

PY - 2007/5

Y1 - 2007/5

N2 - The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

AB - The principle of therapy for chronic inflammatory liver diseases is the removal of causal agents. For autoimmune liver diseases, however, total removal of causal agents and immune cells is impossible. Therefore, autoimmune liver diseases are presently treated by suppression of the immune response. Autoimmune hepatitis is characteristically responsive to corticosteroids, often used in combination with azathioprine to obtain a steroidsparing effect. For primary biliary cirrhosis, ursodeoxycholic acid is safe and is the first choice for treatment. Treatment of this autoimmune liver disease should also address various symptoms and complications arising from any associated autoimmune diseases, particularly cholestasis and cirrhosis-related complications. For primary sclerosing cholangitis there are no established immunomodulatory therapies, but medical, endoscopie, and surgical treatments are applicable to this disease. Liver transplantation becomes indicated during the eventual end stages of each of these immune-mediated liver diseases.

KW - Autoimmune hepatitis

KW - Guideline

KW - Overlapping syndrome

KW - Primary biliary cirrhosis

KW - Primary sclerosing cholangitis

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34249912673&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249912673&partnerID=8YFLogxK

U2 - 10.1055/s-2007-979472

DO - 10.1055/s-2007-979472

M3 - Article

C2 - 17520519

AN - SCOPUS:34249912673

VL - 27

SP - 214

EP - 226

JO - Seminars in Liver Disease

JF - Seminars in Liver Disease

SN - 0272-8087

IS - 2

ER -